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ABSTRACT 
DANIELLE MARIE SCHESWOHL 
INTERACTIONS THAT CONTRIBUTE TO FAK ACTIVATION 
(Under the direction of Michael D Schaller) 
 
    Focal adhesion kinase (FAK) is an important regulatory protein that integrates signals 
from integrins and growth factor receptors to control cell growth, survival, and migration.  
FAK function is tightly regulated and the complete mechanism of activation remains to be 
resolved.  The FAT domain of FAK associates with the scaffolding protein paxillin as a 
major mechanism of FAK localization.  Structural insights have been used to design point 
mutations to disrupt FAK binding to paxillin and resulting defects in FAK function have 
been characterized.  The FERM domain of FAK is thought to play an important role in 
relaying biological signals.  This domain is involved in an intramolecular interaction with the 
FAK catalytic domain that severely inhibits activity.  I hypothesize that FERM domain 
associations disrupt the inhibitory association between the FERM and catalytic domains, thus 
activating FAK.  A mutagenesis strategy has been used to identify binding sites on the FERM 
domain.   
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CHAPTER ONE 
BACKGROUND AND SIGNIFICANCE 
 
    1.1 FAK AND ANGIOGENESIS 
    Angiogenesis- the formation of new blood vessels- is an important process during 
development and throughout life.  Alterations in normal levels of angiogenesis play a role in 
several pathological condit ions such as stroke, coronary artery disease, rheumatoid arthritis, 
psoriasis, diabetic retinopathy, age-related macular degeneration, and cancer (Eliceiri and 
Cheresh, 2001).  During angiogenesis, the new blood vessels are formed by vascular 
endothelial cells (EC), which integrate environmental stimuli to regulate vessel formation 
(Daniel and Abrahamson, 2000;Orr and Murphy-Ullrich, 2004).  The initial step in this 
process is the sprouting of the ECs, which requires migration into the extracellular matrix 
(ECM) (Peng et al., 2004).  This migration is mediated by signals from both integrins and 
growth factor receptors (Eliceiri and Cheresh, 2001;Eliceiri, 2001;Schwartz and Ginsberg, 
2002).  These signals cause the ECs to loosen cell-cell contacts and secrete enzymes that 
degrade the subendothelial basement membrane.  After migration, the ECs assemble a lumen, 
completing the vessel formation; although maturation of the vessels requires further 
processes such as smooth muscle recruitment and organization (Orr and Murphy-Ullrich, 
2004).  EC spreading, migration, and morphogenesis are essential for angiogenesis (Kim et 
al., 2000).  Accordingly, gene targeting studies have revealed roles in vasculogenesis and 
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angiogenesis for angiogenic growth factors, ECM components, and integrin ECM receptors 
(Ilic et al., 2003).   
    FAK is activated by many angiogenic stimuli such as insulin- like growth factor (IGF)-1, 
basic fibroblast growth factor (FGF), angiopoietin-1, EphrinA1, thrombospondin, and TNF-
related activation-induced cytokine (TRANCE).  In many of these cases, FAK activation is 
thought to play an important role in relaying downstream signals (Carter et al., 2002;Kim et 
al., 2002;Orr and Murphy-Ullrich, 2004;Duxbury et al., 2004;Orr et al., 2004).  For example, 
FAK activation has been shown to be required for angiopoietin-1 stimulated EC sprouting 
(Kim et al., 2000).  The most compelling evidence for an essential role for FAK dur ing 
angiogenesis comes from studies of VEGF (Hood et al., 2003;Avraham et al., 2003).  
Stimulation of ECs with VEGF induces Src-dependent phosphorylation of FAK at tyrosine 
861, an event that is essential for VEGF stimulated effects on cell migration and survival 
(Abu-Ghazaleh et al., 2001;Eliceiri et al., 2002).  Using a chick chorioallantoic membrane 
(CAM) angiogenesis assay, inhibition of FAK was shown to disrupt VEGF-mediated Ras 
and c-Raf activity in a Src-dependent manner (Avraham et al., 2003).  It has also been shown 
that the tubulogenesis activity associated with an activated form of VEGFR-1 is dependent 
upon FAK (Maru et al., 2001).  The same study found an association between VEGFR-1 and 
FAK following VEGF stimulation that correlated with tubulogenic ability, further supporting 
a role for FAK during VEGF stimulated angiogenesis (Maru et al., 2001). 
    FAK is important for regulating several processes integral to angiogenesis, such as cell 
growth, survival, and migration (Hanks et al., 2003).  The first insight into a role for FAK in 
the vasculature came from studies which identified a high level of FAK staining in the 
vasculature of the developing mouse embryo (Polte et al., 1994).  The importance of FAK in 
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vascular development was verified upon development of knockout mice that die at 
embryonic day 8.5 due to major defects in vascular development, both in vasculogenesis and 
angiogenesis (Ilic et al., 1995).  There have also been several studies that have manipulated 
FAK signaling in ECs, most commonly by expression of FAK or the FAK dominant negative 
variant FRNK.  The observed effects on angiogenesis or processes important for 
angiogenesis have implicated FAK in the control of EC migration and tubulogenesis.   
 
    1.2 FAK REGULATION OF CELLULAR PROCESSES 
    FAK plays an important role in the regulation of several cellular processes including cell 
spreading, cell migration, cell proliferation, cell survival, and apoptosis.  Regulation of these 
processes is important not only for angiogenesis, but also for development and cancer 
progression.  For these reasons, many studies have investigated the role of FAK in the 
regulation of these processes.  These studies indicate that FAK signaling is mediated by 
binding of FAK to various interacting partners. 
    Several studies have demonstrated a role for FAK in cell spreading on fibronectin.  fak-/- 
MEFs have defects in attachment to fibronectin and reportedly exhibit rounded morphologies 
and are poorly spread compared to fak +/+ MEFs or fak -/- MEFs re-expressing FAK (Westhoff 
et al., 2004).  Furthermore overexpression of the FAK dominant negative FRNK delays cell 
spreading in CE cells (Richardson and Parsons, 1996).  These results suggest a role for FAK 
in the regulation of this important cellular process. 
    FAK has long been implicated in integrin-mediated cell motility.  Overexpression of the 
FAK dominant negative FRNK inhibits migration of endothelial cells in a wound healing 
assay (Gilmore and Romer, 1996).  Alternatively, overexpression of FAK increases cell 
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migration in CHO cells (Cary et al., 1998).  Finally, fak -/- MEFs show reduced rates of cell 
migration (Ilic et al., 1995) that is restored upon FAK re-expression (Owen et al., 1999;Sieg 
et al., 2000).  FAK is thought to regulate cell migration via multiple signaling partners.  p130 
CAS has been shown to regulate migration independently of FAK and a FAK mutant 
defective for p130CAS binding failed to induce cell migration (Cary et al., 1998;Sieg et al., 
2000).  PI3K has also been suggested to mediate FAK effects on cell migration and a FAK 
mutant defective for PI3K binding also failed to induce cell migration (Reiske et al., 1999).  
Finally, Grb7 has been proposed to be required for FAK effects on migration as this protein 
has been independently linked to regulation of cell migration and can bind FAK (Han and 
Guan, 1999;Han et al., 2000).  These studies indicate that FAK plays a critical role in 
regulation of cell migration, possibly via multiple pathways. 
    Several lines of evidence link FAK to regulation of cell proliferation.  Inhibition of FAK 
by expression of FRNK (Gilmore and Romer, 1996) or by injection of FAK monoclonal 
antibody (Hungerford et al., 1996) both result in inhibition of DNA synthesis and cell cycle 
arrest.  Alternatively, expression of FAK positively regulates cell cycle progression 
following serum-stimulation (Zhao et al., 1998b).  FAK is thought to regulate cell cycle 
progression via MAPK signaling to the ERK and JNK MAPKs (Zhao et al., 1998a;Oktay et 
al., 1999).   
    Detachment from the ECM induces apoptosis in many cells types.  Apoptosis due to loss 
of cell attachment is termed anoikis and is regulated by integrins and FAK signaling.  This 
role for FAK in providing resistance to anoikis is supported by several studies.  A membrane-
targeted, activated form of FAK expressed in epithelial cells provided protection from 
apoptosis in these cells (Frisch et al., 1996).  Alternatively, inhibition of FAK by antisense 
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(Xu et al., 1996) or injection of monoclonal FAK antibody (Hungerford et al., 1996) has 
been shown to induce apoptosis in different cell types.  Finally, FAK proteolysis at specific 
sites has been demonstrated in various cell lines undergoing apoptosis, indicating that FAK 
signaling needs to be inhibited in order for apoptosis to proceed in these cells (Crouch et al., 
1996;Wen et al., 1997;Levkau et al., 1998).  FAK associations with both p130CAS and PI3K 
are thought to be important for FAK’s regulation of cell survival (Chan et al., 1999;Bellas et 
al., 2002).  Recent studies have also identified an association between FAK and p53.   This 
association suppresses p53-mediated apoptosis and inhibits p53 transcriptional activity, 
representing an independent pathway by which FAK controls apoptosis (Ilic et al., 
1998;Golubovskaya et al., 2005). 
 
    1.3 FAK ACTIVATION 
    FAK has long been known to play an important role in mediating integrin signaling 
(Hanks et al., 2003;Orr and Murphy-Ullrich, 2004).  When integrins bind to ECM proteins, 
they cluster on the cell surface resulting in clustering of FAK at these sites of adhesion.  FAK 
clustering induces autophosphorylation of Y397, which creates docking sites for proteins 
with SH2 domains, specifically Src, the p85 subunit of PI3K, Grb7, and phospholipase C-? 
(Turner, 2000;Schaller, 2001a).  Once Src binds, it phosphorylates other tyrosine residues in 
FAK resulting in further activation.  Specifically, Y576 and Y577 are located within the 
activation loop of the kinase and phosphorylation of these sites is necessary for maximal 
catalytic activity (Calalb et al., 1995).  Src can also phosphorylate Y861 and Y925 in the C-
terminus of FAK.  Phosphorylation of Y861 downstream of VEGF stimulation contributes to 
the formation of a complex between FAK and the avß5 integrin, necessary for VEGF-
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stimulated migration (Eliceiri et al., 2002).  Phosphorylation of Y925 creates a binding site 
for the SH2 domain of Grb2, which may be important for activation of ERK (extracellular 
signal-related kinase) and for dynamin-mediated focal adhesion disassembly (Hanks et al., 
2003;Orr and Murphy-Ullrich, 2004;Ezratty et al., 2005).  These phosphorylation events are 
required for FAK activation downstream of integrin attachment and are required for FAK 
downstream signaling. 
 
    1.4 FAK DOMAINS 
    FAK is composed of three major domains as shown in Figure 1 (Hanks et al., 2003).  The 
C-terminal FAT domain is necessary and sufficient for the localization of FAK to focal 
adhesions by binding to other focal adhesion proteins like paxillin (Schaller, 2001a).  This 
domain of FAK and its association with paxillin is discussed further in Chapter 2.  An 
alternately spliced form of FAK termed FRNK (FAK-related non-kinase) is composed of the 
C-terminal domain, including the FAT sequences.  FRNK has been shown to act as a 
dominant negative in several systems, disrupting endogenous FAK function.  FAK also 
contains a central catalytic domain that is responsible for phosphorylating various focal 
adhesion proteins, such as paxillin and p130CAS.  The function of the N-terminal FERM 
domain of FAK has until recently remained a mystery.  There have been reports of proteins 
binding to the FAK FERM domain, but the relevance of these interactions has not been 
determined (Schaller, 2001a;Liu et al., 2002).  New insights suggest that this domain is 
involved in an intramolecular interaction with the FAK catalytic domain that negatively 
regulates FAK activity.  This domain of FAK is discussed further in Chapter 3. 
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    1.5 SUMMARY 
        Angiogenesis is an important process during development and throughout life.  
Deviations from normal levels of angiogenesis play a role in several pathological conditions, 
such as stroke and coronary artery disease (Eliceiri and Cheresh, 2001).  During 
angiogenesis, new blood vessels arise from vascular endothelial cells (EC), which integrate 
signals from integrins and growth factor receptors to regulate cell growth, survival, and 
migration (Daniel and Abrahamson, 2000;Eliceiri and Cheresh, 2001;Eliceiri, 2001;Orr and 
Murphy-Ullrich, 2004).  An important protein known to play a role in the regulation of these 
EC processes is the focal adhesion kinase (FAK). FAK is activated by several angiogenic 
stimuli and FAK is important for regulating several processes integral to angiogenesis, such 
as cell growth, survival, and migration.  FAK function is regulated in several ways and 
although much is known about phosphorylation events that play a role in FAK’s activation, 
the complete mechanism of activation still remains to be resolved.   
 
 
 
 
 


  
 
 
 
CHAPTER TWO 
PAXILLIN BINDING IS IMPORTANT FOR FAK LOCALIZATION, 
BIOCHEMICAL, AND BIOLOGICAL FUNCTION 
 
   2.1 INTRODUCTION 
    Focal adhesion kinase is a non-receptor tyrosine kinase that plays an important role in 
mediating essential cellular processes, such as cell growth, survival, and migration.  FAK 
knockout mice die at E8.5, exhibiting developmental defects similar to those seen in FN-
deficient and ß1 integrin knockout mice (Watt and Hodivala, 1994;Hirsch et al., 1996).  
Fibroblasts isolated from fak -/- mice are more rounded or pancake-shaped, have more focal 
adhesions, and have a migratory defect as compared to cells from wild type littermates (Ilic 
et al., 1995).  In accordance with the phenotype of the fak -/- mice, FAK has long been known 
to play an important role in mediating integrin signaling (Schaller, 2001a;Hanks et al., 2003).   
    When integrins bind to ECM proteins, they cluster on the cell surface resulting in 
clustering of FAK at these sites of adhesion, called focal adhesions.  FAK clustering induces 
autophosphorylation of Y397, which creates docking sites for proteins with SH2 domains, 
specifically Src, the p85 subunit of PI3K, Grb7, and phospholipase C-? (Turner, 2000).  Src 
binding is considered an important event as it subsequently phosphorylates other tyrosine 
residues in FAK.  Y576 and Y577 are located within the activation loop of the kinase and 
phosphorylation of these sites by Src is necessary for maximal catalytic activity of FAK
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 (Calalb et al., 1995).  Src can also phosphorylate Y861 and Y925 in the C-terminus of FAK.  
Phosphorylation of Y861 downstream of VEGF stimulation promotes the formation of a 
complex between FAK and the avß5 integrin, which is necessary for VEGF-stimulated 
migration (Eliceiri et al., 2002).  Phosphorylation of Y925 creates a binding site for the SH2 
domain of Grb2 and may be important for activation of ERK (extracellular signal-related 
kinase) (Chen et al., 1995;Schlaepfer and Hunter, 1996;Schaller, 2001a;Hanks et al., 2003).  
Grb2 binding to Y925 also recruits dynamin to focal adhesions, which is important for focal 
adhesion disassembly (Ezratty et al., 2005).  Thus, these Src-dependent phosphorylation 
events play an important role in regulation of FAK signaling downstream of integrin 
attachment. 
    FAK is composed of three major domains (Schaller, 2001a;Hanks et al., 2003).  The N-
terminal FERM domain of FAK contains binding sites for a number of proteins and has 
recently been reported to interact with the catalytic domain of FAK to inhibit catalytic 
activity (Cooper et al., 2003;Dunty et al., 2004).  FAK contains a central catalytic domain 
that is responsible for phosphorylating various focal adhesion proteins, such as paxillin, 
p130CAS, and tensin.  The C-terminal focal adhesion targeting (FAT) domain is required for 
the localization of FAK to focal adhesions and binds to two focal adhesion associated 
proteins, paxillin and talin (Hildebrand et al., 1993;Hildebrand et al., 1995). 
    Paxillin is a scaffolding protein composed of multiple protein-protein interaction domains, 
including five N-terminal LD motifs, four C-terminal LIM domains, and SH2 and SH3 
domain binding sites (Schaller, 2001b).  The second and fourth LD motifs of paxillin have 
been identified as FAK-binding sites and each of these sites binds to FAK with similar 
affinity (Thomas et al., 1999).  Paxillin is localized to focal adhesions by interactions 
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mediated by its C-terminal LIM domains (Schaller, 2001b) and paxillin is known to be one of 
the first proteins recruited into these structures as they are formed (Webb et al., 2004).  
Binding to paxillin is proposed as one mechanism of localization of FAK to focal adhesions 
and association with talin has been suggested as an alternative mechanism of localization.  
Results from paxillin knockout studies show reduced phosphorylation of FAK in paxillin-/- 
embryonic stem cells (Wade et al., 2002) and in paxillin-/- cultured mouse embryonic 
fibroblasts (Hagel et al., 2002).  This indicates that paxillin binding may function in the 
regulation of FAK activity, in addition to its proposed role in regulating localization.   
    Recent reports have used both NMR and crystallographic approaches to determine the 
structure of the C-terminal FAT domain of FAK as a four-helix bundle (Arold et al., 
2002;Hayashi et al., 2002;Liu et al., 2002;Gao et al., 2004;Bertolucci et al., 2005).   
Additional structural studies have also revealed the structure of the FAT domain of FAK in 
complex with peptides mimicking the LD2 peptide of paxillin (Gao et al., 2004;Bertolucci et 
al., 2005).  The striking finding from these studies was the identification of two paxillin-
binding sites on the FAT domain of FAK.  This finding is particularly intriguing, given the 
presence of two FAK-binding sites in the N-terminus of paxillin.  Each paxillin-binding site 
in the FAT domain is composed of a surface exposed hydrophobic patch, adjacent to a series 
of basic residues.  One binding site lies at the interface of a-helices 2/3 and the other at the 
interface of a-helices 1/4 and thus the two sites are on opposite sides of the four-helix 
bundle.  While evidence suggests that the LD2 peptide of paxillin interacts with both of these 
sites with similar affinity (Gao et al., 2004), the results of a paramagnetic labeling 
experiment suggests that the paxillin LD4 peptide has a preference for one site over the other 
(Bertolucci et al., 2005).   
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    These studies raise an interesting question of whether the two paxillin-binding sites of 
FAK are simply redundant interaction surfaces that strengthen the association between these 
two proteins, or alternatively, whether paxillin binding to each site might mediate a distinct 
function.  To address these important questions, site-directed mutagenesis of the paxillin-
binding regions on FAK was used to disrupt binding to the a-helix 2/3 paxillin binding site 
(E949A/K956A/R963A or EKR) or to the a-helix 1/4 paxillin binding sites (I937A), 
respectively.  Combining these mutations together (E949A/K956A/R963A/I937A or 
EKR/I937A) completely abolished paxillin binding as demonstrated in vitro by GST 
pulldown and in vivo by co- immunoprecipitation as previously reported (Gao et al., 2004).  
These mutants have been characterized to determine the role of paxillin binding to each site 
individually or to both binding sites in the function of FAK. 
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    2.2 MATERIALS AND METHODS 
    Molecular biology.  FAK mutants were engineered using pBluescript-FAK as a template 
(Schaller et al., 1992).  Point mutations were engineered using the QuikChange mutagenesis 
kit (Stratagene, La Jolla CA).  Sequence analysis was performed to verify the intended point 
mutations and that no unintended mutations were present.  These analyses were performed in 
the UNC-CH Genome Analysis Facility on a model 3730 DNA Analyzer (Perkin Elmer, 
Applied Biosystems Division) using the ABI PRISMTM Dye Terminator Cycle Sequencing 
Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Perkin Elmer, Applied 
Biosystems Division).  Full- length FAK cDNAs were subcloned into RCAS A as described 
previously (Hildebrand et al., 1993).  Full- length FAK cDNAs were subcloned into pEGFP 
as described previously (Cooley et al., 2000).  Full- length FAK cDNAs were excised from 
pBluescript using BamHI and SalI and inserted into the multiple cloning site of the pBABE 
vector.  All subcloned constructs were verified by sequence analysis.  Point mutations were 
engineered into pEGFP-EKR/I937A using the QuikChange XL Site-Directed Mutagenesis 
Kit (Stratagene, La Jolla CA).  Sequence analysis was performed on each mutant to verify 
the intended point mutations and that no unintended mutations were present.   
 
    Cells and viruses. Chicken embryo (CE) cells were prepared and maintained as described 
previously (Reynolds et al., 1989).  These cells were transfected using Lipofectamine PLUS 
(Life Technologies, Gaithersburg, MD) with RCAS A retroviral vectors encoding wild type 
or mutant FAK proteins (Gao et al., 2004).  To address the regulation of FAK 
phosphorylation in response to adhesion,  cells were trypsinized, washed in 0.5 mg/mL 
soybean trypsin inhibitor (Sigma, St. Louis, MO) in PBS, held in suspension for 30 minutes, 
 15 
and replated onto dishes coated with fibronectin (50 µg/ml) for 45 minutes.  In order to 
enhance the phosphotyrosine content of cellular proteins in some experiments, cells were 
treated with 50 µM sodium vanadate for 16 hrs prior to lysis.   
    CHO cells were maintained as described (Webb et al., 2004).  To generate stable 
populations of CHO cells expressing GFP tagged constructs, the cells were transfected with 
plasmids encoding wild type FAK or mutants fused to GFP using Lipofectamine PLUS (Life 
Technologies), followed by selection and maintenance in 1 mg/ml G418 (Gibco BRL).  
Populations of G418 selected CHO cells were then sorted by FACS to enrich for GFP 
expression.  Trypsinized CHO cells were washed once in PBS then resuspended in 0.5 ml 
PBS.  Flow cytometry was performed on a Becton Dickinson FACScan interfaced to a 
Cytomation, Inc. Cicero data acquisition system in the UNC Flow Cytometry Facility.   
    Fak-/- MEFs were maintained as described (Westhoff et al., 2004).  In order to generate 
populations of fak -/- MEFs expressing wild type or FAK mutants, the pBABE retroviral 
vector was used.  To generate virus to infect the fak -/- MEFs, Phoenix cells were transfected 
with the various pBABE constructs.  Phoenix cells were maintained in DMEM F12 (Gibco 
BRL, Rockville, MD) supplemented with 10% FBS (Gibco BRL), penicillin, streptomycin, 
gentamicin and kanamycin (Sigma).  Phoenix cells were transfected with 8 µg pBABE DNA 
using Lipofectamine PLUS (Life Technologies).  After 48 hrs, virus-containing media was 
collected and filtered through a 0.45 µm syringe filter.  For infection, each dish of fak -/- MEFs 
was incubated for 24 hrs with 4 mL filtered virus-containing media, 4 µg/mL polybrene 
(Sigma), and 5 mL complete media.  At 24 hrs, the infection media was replaced with 
complete media.  At 48 hrs post- infection, media was replaced with complete media 
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containing 2 µg/mL puromycin (Sigma) for selection and maintenance of expressing 
populations. 
 
    Cell adhesion assay.  Cell adhesion assays were performed as described previously 
(Westhoff et al., 2004).  Drug selection media was removed from cells overnight.  Cells were 
trypsinized, washed once with PBS containing 0.5 mg/mL soybean trypsin inhibitor (Sigma), 
once with serum-free DMEM, and resuspended in serum-free DMEM containing 0.5 mg/mL 
lipid-free BSA (Sigma).  Cells were held in suspension for 1 hr at 37oC prior to plating onto 
fibronectin-coated surfaces.  Bacteria l 60 mm dishes were coated at 4oC with 50 µg/mL 
bovine plasma fibronectin (Sigma) overnight then blocked for 1 hr with DMEM containing 
0.5 mg/mL lipid-free BSA (Sigma).  1x105 cells were added to each 60 mm dish and 
incubated at 37oC for 60 minutes, followed by fixation and staining using a Hema3 kit 
(Fisher Diagnostics, Middletown, VA) according to manufacturer’s instructions.  The 
number of cells in five random fields was counted for each experiment. 
 
    Protein analysis. Cells were washed twice with PBS and lysed in modified RIPA buffer 
(50 mM Tris [pH 7.3], 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate) containing 
protease and phosphatase inhibitors as described previously (Gao et al., 2004).  Protein 
concentrations were determined with the bicinchoninic acid assay (Pierce, Rockford, Ill.). 
The FAK phosphorylation site-specific antibodies (Biosource International, Camarillo, CA) 
and paxillin, p130CAS, and PY20 phosphotyrosine antibodies (BD Biosciences, San Diego, 
CA) were purchased commercially.  The BC4 polyclonal antiserum has been described 
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previously (Schaller et al., 1992).  Immunoprecipitations and Western blotting were 
performed as previously described (Gabarra-Niecko et al., 2002).  
 
    Immunofluorescence. Glass coverslips were coated with 50 µg/mL bovine plasma 
fibronectin (Sigma) in PBS for 1 hr at 37 °C. Cells were plated onto the coated coverslips and 
maintained at 37°C for 16 hr.  Cells were fixed in 3.7% formaldehyde and permeabilized 
with 0.5% Triton X-100.  FAK was detected using BC4 and rhodamine-conjugated anti-rabbit 
antibody (Jackson ImmunoResearch Labs).  For co-staining studies, a paxillin monoclonal 
antibody (BD Biosciences) and rhodamine conjugated anti-mouse secondary antibodies 
(Jackson Labs) were used to visualize focal adhesions while an avian GFP antibody 
(Chemicon International, Temula, CA) and FITC anti-chicken secondary antibodies (Jackson 
Labs) were used to detect GFP-tagged proteins.  Cells  were visualized using a Leitz 
Orthoplan fluorescence microscope, and images captured with a Hamamatsu digital camera 
and Metamorph imaging software (Universal Imaging Corporation, West Chester, PA).  
Images were taken with identical exposure times.  Paxillin staining was used to identify focal 
adhesions and cells were scored for co- localization of paxillin and GFP staining, indicating 
FAK localization at these sites.  The results were expressed as percentage of cells exhibiting 
focal adhesion localization of GFP-FAK to focal adhesions.  ANOVA analyses with Dunnett 
post-tests were performed using GraphPad software (San Diego, CA) to identify statistically 
significant differences in localization efficiency.  For live cell imaging, EGFP N-terminally 
tagged forms of wild type FAK or the FAK mutants were expressed in CE cells using 
Lipofectamine PLUS (Invitrogen).  At 24 hrs, the transfected cells were plated in 35 mm 
glass bottom dishes (MatTek, Ashland, MA) and incubated overnight at 37oC.  At 48 hrs, 
 18 
cells were viewed using an Olympus IX81 microscope by epiflourescence and TIRF 
microscopy.  
 
    Protein preparation and in vitro binding experiments.  GST fusion proteins were 
expressed in E. coli and purified as described (Gabarra-Niecko et al., 2002).  Briefly, 
expression was induced with 0.1 mM isopropyl 1-thio-ß-D-galactopyranoside, followed by 
incubation for 2 hrs at 37oC.  The bacteria were harvested and sonicated in TETN buffer (1% 
Triton X-100, 20 mM Tris [pH 8.0], 100 mM NaCl, 1 mM EDTA) plus protease inhibitors (1 
mM PMSF, 10 µg/mL leupeptin, 10 Ug/mL aprotinin).  Clarified supernatants were bound to 
glutathione-agarose beads (Sigma) for 1 hr at 4oC, washed three times with PBS, and 
resuspended in equal volumes PBS.  Fusion proteins were quantified by SDS/PAGE and 
Coomassie blue staining.  For binding experiments, 1 mg of vanadate-treated CE lysate was 
precleared by incubation with 100 µg of GST bound to glutathione-agarose beads for 1 hr at 
4oC, then incubated with 25 µg GST-Grb2SH2 immobilized on beads for 2 hrs at 4oC.  The 
beads were washed twice with modified RIPA buffer, twice with PBS, eluted in sample 
buffer, and analyzed by western blotting. 
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    2.3 RESULTS 
    To determine if there is a specific role for each paxillin-binding site of the FAT domain of 
FAK, mutants that disrupt binding to paxillin at each site individually or to both sites 
simultaneously have been generated.  Wild type FAK or the FAK mutants were expressed in 
primary chicken embryo (CE) cells using the RCAS A retroviral vector, in fak -/- MEFs using 
the pBABE retroviral vector, and as GFP fusion proteins in CHO cells.  Cells were lysed and 
expression levels examined by western blotting.  Expression of each mutant was comparable 
to that of wild type FAK in each of these cell systems, as shown in Figure 3.  Further, 
expression levels in CHO cells and the MEFs was similar to the normal level of expression of 
endogenous FAK. 
    Paxillin is known to have two binding sites for FAK and mutants of paxillin that disrupt 
binding to FAK have been previously described (Thomas et al., 1999).  Recent studies have 
revealed that FAK also has two binding sites for paxillin.  To assess the ability of individual 
binding sites on paxillin and FAK to interact, a GST pulldown approach was utilized.  GST 
fusion proteins, shown in Figure 4A, were used to bind to FAK variants expressed in CE 
cells.  The GST fusion proteins contained the N-terminal portion of paxillin containing both 
FAK binding sites, i.e. LD 2 and LD 4 (GST-PaxN1C3).  GST fusion proteins with point 
mutations that disrupt FAK binding to LD2 (D146A) or LD4 (D268A) were also used, as 
well as a double mutant that abolishes FAK binding to both LD2 and LD4 (D146A/D268A).  
Fusion proteins, immobilized on glutathione beads, were incubated with lysates of CE cells 
expressing FAK variants and bound FAK assessed by western blotting.  Wild type FAK 
bound to the wild type recombinant paxillin, exhibited slightly reduced binding to both the 
D146A and D268A mutants, and bound poorly to the D146A/D268A double mutant.  These 
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observations are similar to published results using these paxillin mutants (Thomas et al., 
1999).  The same trend is observed with the I937A FAK mutant, i.e. reduced binding to the 
D146A and D268A mutants and poor binding to the D146A/D268A double mutant.  In 
contrast, the EKR FAK mutant exhibits a different pattern of binding.  This FAK mutant 
binds the wild type paxillin fusion protein and shows reduced binding to the D268A mutant.  
This FAK mutant binds very poorly to the D146A mutant and the D146A/D268A double 
mutant.  This differential binding reveals that the two FAK-binding sites of paxillin do not 
interact with FAK in precisely the same way.  While the LD2 motif of paxillin (this site is 
intact in the D268A mutant) interacts with FAK mutants defective for paxillin binding at 
either site in the FAT domain, the LD4 motif of paxillin (this site is intact in the D146A 
mutant) preferentially interacts with the I937A mutant of FAK.  Thus the LD4 motif 
preferentially associates with the intact paxillin-binding site in this mutant, which is at the 
interface of a-helices 2 and 3. 
    The subcellular localization of FAT domain mutants was assessed by immunofluorescence 
of exogenously expressed protein.  CE cells expressing FAK were plated onto fibronectin-
coated coverslips and allowed to adhere overnight.  Coverslips were fixed, permeabilized, 
and stained with a FAK polyclonal antibody and FITC-anti-rabbit secondary antibody.  The 
exogenous proteins are expressed at high levels making it easy to distinguish their 
expression.  Examples of cells exhibiting focal adhesion localization of each of the FAK 
mutants are shown in Figure 5A.  To validate these findings, a complimentary approach 
using GFP-tagged FAK variants was used to assess localization.  GFP fused to wild type 
FAK or the FAK mutants were transiently expressed in CE cells.  At 24 hrs post-transfection, 
the cells were plated onto glass-bottom dishes and 24 hours later, the cells were viewed by 
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epiflourescence and TIRF microscopy.  Although transfection efficiency is low in these cells, 
sufficient numbers of cells could be analyzed, as shown in Figure 5B.  For each of the 
mutants, there were cells exhibiting focal adhesion localization of FAK by both 
epiflourescence and TIRF microscopy.  These experiments revealed that mutants of FAK that 
disrupt paxillin binding to either site on the FAT domain or to both sites can still localize to 
focal adhesions.  However, during the course of imaging the transfected CE cells it was 
apparent that some of the mutants were more difficult to find at focal adhesions, suggesting 
there might be a quantitative difference in efficiency of localization.  To further investigate 
the subcellular localization of these mutants, stable populations of CHO cells expressing 
GFP-FAK fusion proteins at a similar level as endogenous FAK protein were established.  
Cells were plated on glass coverslips and allowed to spread overnight before being fixed and 
stained using an avian GFP antibody (Chemicon International) and FITC secondary antibody.  
Focal adhesions were stained using a paxillin monoclonal antibody and a rhodamine- labeled 
secondary antibody.  Fixed cells were imaged (data not shown) and paxillin staining was 
used to identify focal adhesions.  Cells were scored for co- localization of paxillin and GFP 
staining, indicating FAK localization at these sites.  The results were expressed as percentage 
of cells exhibiting focal adhesion localization of GFP-FAK (Figure 6A).  Like wild type 
FAK, the EKR FAK mutant was targeted to focal adhesions in about 90% of the cells.  The 
I937A mutant was localized to focal adhesion in about 55% of the cells, indicating that this 
paxillin-binding site may be more important for focal adhesion targeting than the other 
paxillin-binding site.  Although some cells expressing the mutant EKR/I937A, which has 
defects in both paxillin-binding sites, exhibit focal adhesion localization of the FAK mutant, 
the efficiency of targeting was severely decreased as compared to wild type FAK.  These 
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results indicate that although paxillin binding is not absolutely required for FAK localization, 
this association does play a role in FAK’s ability to localize to focal adhesions.  
    Although the above experiments indicated that paxillin plays a major role in the regulation 
of FAK targeting to focal adhesions, the FAK mutant defective for paxillin binding still 
correctly localized in approximately 10% of cells.  This mutant presents a suitable 
background for additional mutagenesis studies to identify residues outside of the paxillin-
binding regions of the FAT domain that are important for FAK localization.  Additional 
alanine substitutions at conserved residues on the surface of the FAT domain were made and 
the subcellular localization of the resulting mutants was assessed upon transient expression as 
GFP fusion proteins in CE cells.  Using this approach, E997 was identified as a residue 
important for FAK localization to focal adhesions in the absence of paxillin binding (Figure 
6B).  This mutant was further analyzed by stable expression of the GFP fusion protein in 
CHO cells.  The E997A mutation in combination with the EKR/I937A mutations resulted in 
a complete absence of the FAK mutant from focal adhesions.  However, the E997A mutant 
in an otherwise wild type background, i.e. with intact paxillin-binding sites, was able to 
localize to focal adhesions nearly as well as wild type FAK (Figure 6A).  This result 
indicates that E997 is important for the localization of FAK to focal adhesions in the absence 
of paxillin binding. 
    FAK phosphorylation is important for its activation and downstream signaling.  CE cells 
expressing either wild type FAK or FAK mutants were used to assess defects in FAK 
phosphorylation when paxillin binding to either or both paxillin-binding sites is dis rupted.  
Phospho-specific antibodies were used to assess the activation state of FAK in cells growing 
in culture and of cells stimulated by cell adhesion to fibronectin.  Once expression of the 
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mutants was confirmed, cell lysates were used for western blotting using phospho-specific 
antibodies to FAK PY397, PY576, PY577, and PY861, as shown in Figure 7A.  These results 
indicate that Y397 is phosphorylated comparably on wild type and mutant FAK proteins.  
This site is the major autophosphorylation site of FAK.  This experiment indicates that 
paxillin binding is not required for FAK to autophosphorylate itself in cells growing in 
culture.  Phosphorylation of Y861, like that of Y397 is not dependent upon paxillin binding 
as mutants that disrupt binding to individual or both sites have no effect on phosphorylation 
of Y861.  In contrast, phosphorylation of Y576 and Y577 in cells growing in culture is 
dependent upon paxillin binding.  Both of these sites in the activation loop of the kinase 
show reduced phosphorylation when paxillin binding is disrupted.  In fact, phosphorylation at 
these sites is reduced in mutants with a single functional paxillin-binding site. 
    Phosphorylation of FAK was also measured from cells stimulated by cell adhesion.  Cells 
were trypsinized, held in suspension, and plated onto a plastic dish coated with fibronectin.  
Cell lysates were analyzed using phospho-specific antibodies.  These results, shown in Figure 
7A, indicate that Y397 and Y861 are phosphorylated in each of the mutants comparably to 
wild type FAK following cell adhesion.  Phosphorylation of Y576 and Y577 is dependent 
upon paxillin binding following cell adhesion since phosphorylation was reduced in all 
mutants that disrupt paxillin binding to at least a single paxillin-binding site in FAK.   
    The FAT domain of FAK contains one known phosphorylated tyrosine at residue 925.  
This site is known to bind Grb2 to signal to the MAPK pathway or recruit dynamin into 
complex.  A GST pulldown approach was taken to assess phosphorylation of Y925.  CE cells 
expressing wild type or mutant forms of FAK were treated overnight with 50 µM sodium 
vanadate before lysis in order to prevent dephosphorylation of cellular proteins.  Lysates 
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were used to bind GST-fusion proteins containing the SH2 domain of Grb2 as shown in 
Figure 7B.  FAK protein from lysates expressing wild type FAK bind GST-Grb2SH2 well, 
while all mutants that disrupt paxillin binding dramatically reduce Grb2SH2 binding to 
background levels.  This experiment indicates that paxillin binding is required for Src 
phosphorylation of Y925, as mutations that disrupt paxillin bind ing to individual or both 
paxillin-binding sites abolished Grb2SH2 binding to FAK. 
    To assess downstream signaling of the various FAK FAT domain mutants, 
phosphorylation of FAK substrates was measured as previously described (Gabarra-Niecko 
et al., 2002).  Briefly, CE cells expressing wild type or mutant forms of FAK were vanadate 
treated to prevent dephosphorylation of cellular proteins.  Lysates were used to 
immunoprecipitate FAK substrates p130CAS and paxillin.  Immunoprecipitated proteins 
were separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with a 
phosphotyrosine antibody, as shown in Figure 8.  The results indicate a further role for 
paxillin binding in FAK downstream signaling since phosphorylation of FAK substrates was 
decreased when paxillin binding defective mutants were expressed.  In this experiment, 
mutants at either paxillin-binding site exhibited reduced phosphorylation of FAK substrates, 
while mutants with disrupted paxillin binding to both sites failed to induce phosphorylation 
of both p130CAS and paxillin.  This experiment did not reveal any differences in signaling 
downstream of the EKR and I937A mutants of FAK, suggesting that both paxillin-binding 
sites are equally important for phosphorylation of these two substrates when FAK is 
expressed in cells. 
    To assess biological effects of these mutations on FAK function, fak -/- MEFs stably 
expressing the various mutants or wild type FAK were used in cell attachment assays as 
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described in the materials and methods.  Briefly, cells were held in suspension, followed by 
plating on fibronectin for 60 minutes.  Cells were fixed and attached cells were counted.  
These experiments revealed a defect in attachment in fak -/- MEFs expressing each of the FAK 
mutants that disrupt paxillin binding.  Mutation of either individual paxillin-binding site or of 
both binding sites simultaneously resulted in a defect in adhesion to FN-coated dishes.  This 
experiment indicates that both paxillin-binding sites play an important role in FAK’s ability 
to control cell attachment to FN. 
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    2.4 DISCUSSION 
    This study has provided interesting insights into the association between FAK and paxillin.  
Recent structural analyses have revealed that FAK has two binding sites for paxillin.  This 
raises the question of whether these binding sites are simply redundant, whether they act in 
concert, or whether engagement of distinct binding sites results in different biochemical or 
biological outcomes.  Site directed mutagenesis was used to disrupt paxillin binding to each 
individual binding site or to both binding sites on the FAK FAT domain.  The results indicate 
that the two binding sites do behave differently to regulate certain FAK functions such as 
localization, but behave similarly to regulate other FAK functions such as downstream 
signaling. 
    A previous study determined that the binding affinities of the two paxillin-binding sites on 
the FAT domain for a peptide mimicking the LD2 motif of paxillin were similar, 
approximately 10 micromolar (Gao et al., 2004).  Further, ITC analysis demonstrated that the 
I937A mutation abolished binding of the peptide to one paxillin-binding site and the EKR 
mutation abolished binding of the peptide to the other paxillin-binding site.  It was therefore 
anticipated that the two binding sites would contribute equally to binding of full- length 
paxillin.  However, binding studies using recombinant GST-paxillin fusion proteins and co-
immunoprecipitation experiments demonstrated that the two paxillin-binding sites do not 
contribute equally to binding to full- length paxillin.  Both approaches showed substantially 
more paxillin binding to the I937A mutant than to the EKR mutant.  Thus, the integrity of the 
paxillin-binding site comprised of a-helices 2/3 of the FAT domain of FAK is more 
important for the interaction with full- length paxillin than the other binding site.  Since the 
binding affinity of both sites for the LD2 motif was the same, the observation could be 
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explained if there were differences in the affinity of the two sites for the LD4 motif.  In fact, 
a recent report using paramagnetic labeling demonstrated that the LD4 of paxillin has a 
preference for the paxillin-binding site between a-helices 2/3 (Bertolucci et al., 2005).  
Using recombinant fragments of paxillin, with mutations impairing one or the other FAK-
binding site, a similar conclusion has been drawn here, i.e. that the LD4 motif preferentially 
interacts with the paxillin-binding site on the a-helices 2/3 side of the FAT domain.  Thus, 
this binding site can associate with both FAK-binding sites on paxillin, whereas the binding 
site composed of a-helices 1/4 associates with the LD2 binding site. 
    Although paxillin binding is not absolutely required for FAK subcellular localization, it is 
the major mechanism of focal adhesion localization.  When paxillin binding is abolished, 
only about 10% of cells display correct localization of FAK.  Further, the I937A FAK mutant 
was more defective for localization to focal adhesions than the EKR FAK mutant.  This 
seems surprising considering that the EKR FAK mutant exhibits reduced binding to paxillin 
by GST pulldown or co- immunoprecipitation compared with the I937A FAK mutant (Gao et 
al., 2004).  This indicates that paxillin binding does not precisely correlate with focal 
adhesion localization.  For subcellular localization of FAK, the paxillin-binding site 
comprised of a-helices 2/3 is more important than paxillin-binding site comprised of a-
helices 1/4. 
    Glutamic acid 997 was identified as an important residue for localization in the absence of 
paxillin binding.  As shown in Figures 6B and C, in the background of a FAK mutant that is 
unable to bind to paxillin, mutation of this residue to alanine completely abolished focal 
adhesion localization, but in a wild type FAK background, this mutation does not 
significantly affect focal adhesion localization.  Binding to this residue may represent a 
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secondary, less efficient mechanism by which FAK can be localized to focal adhesions in the 
absence of paxillin binding.  Talin is a focal adhesion protein that has been reported to bind 
to the FAT domain of FAK and has been suggested to function as a mechanism for FAK 
subcellular localization.  It is possible that E997 is an important residue for the association 
between FAK and talin.  However, we have been unable to test this hypothesis, as we have 
been unable to detect the interaction between the FAT domain of FAK and talin by co-
immunoprecipitation, GST pulldown or direct binding between purified recombinant 
proteins.  Alternatively, E997 might be important for interaction with another binding partner 
and the E997A mutant might be a useful tool for the identification of additional 
physiologically relevant binding partners. 
    Phosphorylation of FAK is important for associa tion with binding partners and for 
maximal catalytic activity.  Results from paxillin null cells suggest paxillin binding is 
essential for maximal FAK phosphorylation.  The paxillin-binding defective FAK mutants 
have provided additional insight.  When paxillin binding is abolished with the EKR/I937A 
mutant of FAK and focal adhesion localization is dramatically reduced, the ability of FAK to 
autophosphorylate on Y397 is not affected.  Similarly, phosphorylation of Y861, which is a 
Src substrate, is not affected. However phosphorylation of Y576 and Y577, the Src 
phosphorylation sites in the activation loop of FAK, is impaired in this mutant.  Several 
studies have indicated that the Y861 Src phosphorylation site on FAK is regulated differently 
than phosphorylation of the other Src sites on FAK, so this finding that Y576/Y577 and 
Y861 are differentially affected is not completely surprising.  Interestingly, mutants with 
defects in a single paxillin-binding site show similar defects in phosphorylation of Y576 and 
Y577, suggesting that engagement of both paxillin-binding sites is required for maximal 
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phosphorylation of these sites.  The fact that each of the paxillin-binding mutants show 
similar defects in phosphorylation of FAK indicates that phosphorylation of FAK at the 
activation loop sites does not precisely correlate with the ability of FAK to localize to focal 
adhesions.  Paxillin binding to both sites on FAK may be required to allow Src binding to 
FAK, perhaps by tethering FAK to focal adhesions more securely.  However, as Y397 
phosphorylation is not altered, such a mechanism would indicate a defect in Src recruitment 
downstream of FAK autophosphorylation.  A more likely scenario is that paxillin binding to 
both sites on FAK may cluster FAK proteins, thus facilitating Src phosphorylation of FAK.  
    As phosphorylation of the activation loop residues is required for FAK maximal catalytic 
activity, it is not surprising that phosphorylation of the FAK substrates paxillin and p130CAS 
is impaired in cells expressing paxillin-binding defective mutants.  The more severe defect in 
substrate phosphorylation observed in cells expressing the EKR/I937A mutant is likely due 
to the localization defect exhibited by the mutant resulting in the spatial segregation of the 
kinase and its substrates.   
 
 
 







  
 
 
 
CHAPTER THREE 
THE FERM DOMAIN OF FAK 
 
    3.1 INTRODUCTION 
    The FERM domain of FAK is composed of three lobes, one ubiquitin- like, one acyl-CoA 
binding protein- like, and one PH domain- like lobe.  Although the folded structure of these 
lobes resembles the structure of known proteins, the functions of the individual lobes are not 
conserved.  In general, FERM domains in other proteins have been shown to be important for 
mediating protein-protein interactions of two particular types.  1) These domains have been 
shown to be important for intramolecular or homophilic intermolecular interactions.  2) 
FERM domains have been shown to play a role in mediating interactions with cytoplasmic 
tails of transmembrane proteins, like integrins (Louvet-Vallee, 2000).   
    The FERM domain of FAK has recently been described to interact with unknown residues 
in the catalytic domain.  This interaction between domains decreases autophosphorylation at 
Y397 and inhibits phosphorylation of other tyrosine residues, severely inhibiting the 
biochemical and biological activity of FAK (Toutant et al., 2002;Cooper et al., 2003;Dunty 
et al., 2004;Cohen and Guan, 2005).  The mechanism that relieves this autoinhibition is not 
clear at this time.  A series of point mutations in the FERM domain, termed KAKTLR 
(K216A/K218A/R222A), results in a form of the kinase that is partially defective for 
activation following cell adhesion, although this mutation does not affect binding of the 
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FERM domain to the catalytic domain directly.  Presumably, the KAKTLR mutation disrupts 
some interaction that helps relieve the intramolecular inhibition of FAK (Dunty et al., 2004).  
This intramolecular inhibition represents a novel mechanism for regulation of FAK 
activation. 
    Recently the FERM domain has also been shown to interact with PDGFR and EGFR in 
fibroblasts (Sieg et al., 2000).  This domain was required for EGF-stimulated cell migration 
in that same study (Sieg et al., 2000).  The FERM domain has also been reported to bind to 
other proteins with established roles in FAK-regulated cellular processes, such as Etk and 
EphA2.  Using large deletion mutants, the interaction between the FERM domain of FAK 
with the PH domain of Etk was found to be necessary for the migratory potential of 
HUVECs, thus implying that interactions with the FERM domain can be critical for FAK 
function (Chen et al., 2001).  
    Although much is known about phosphorylation events that play a role in FAK’s 
activation, the complete mechanism of FAK activation remains to be determined.  The role of 
the FERM domain of FAK remains to be elucidated.  I hypothesize that FERM domain 
binding to growth factor receptors and/or other cytoplasmic proteins regulates FAK 
activation by disrupting the inhibitory association between the FERM and catalytic domains, 
as illustrated in Figure 2.  To address these questions, a mutagenesis strategy in conjunction 
with both biochemical and biological assays has begun to identify binding sites, with the 
intention to characterize the relevance of these interactions for FAK activation and biological 
activity. 
    For this study, point mutations were designed and screened in fibroblasts using 
biochemical and biological assays to identify mutants that disrupt interactions with known 
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binding partners and to identify mutant s that affect activation or biological activities of FAK.  
In addition to the novel FERM domain mutants used in these studies, the previously 
published KAKTLR FERM domain mutant was also further characterized. 
    Based on evolutionary conservation between species, searches for known binding motifs, 
and using the structure of the FERM domain of FAK, novel point mutations were designed.  
These FERM domain mutations are shown in Table I.  To study interactions with these 
various mutants, they were subcloned into multiple expression vectors to use in different 
systems.  These mutants have been expressed as GFP-fusion proteins in 293 cells and CE 
cells for transient experiments.  The mutants have also been stably expressed in fak -/- MEFs 
to assess their abilities to restore FAK function in these cells.   
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    3.2 MATERIALS AND METHODS 
    Cells and viruses.  293 cells were maintained in DMEM F12 (Gibco BRL, Rockville, MD) 
supplemented with 10% FBS (Gibco BRL).  293 cells were transfected with 2 µg pEGFP 
DNA using Lipofectamine PLUS (Life Technologies).  fak-/- MEFs were used in these 
studies to address the role of wild type or FAK mutants in cells lacking FAK expression.  fak-
/- MEFs were maintained as described (Westhoff et al., 2004).  In order to generate 
populations of fak -/- MEFs expressing wild type or FAK mutants, the pBABE retroviral 
vector was used.  To generate virus to infect the fak -/- MEFs, phoenix cells were transfected 
with the various pBABE constructs.  Phoenix cells were maintained in DMEM F12 (Gibco 
BRL, Rockville, MD) supplemented with 10% FBS (Gibco BRL), penicillin, streptomycin, 
genamycin and kanamycin (Sigma).  Phoenix cells were transfected with 8 µg pBABE DNA 
using Lipofectamine PLUS (Life Technologies).  After 48 hrs, virus-containing media was 
collected and filtered through a 0.45 µm syringe filter.  For infection, each dish of fak -/- MEFs 
was incubated for 24 hrs with 4 mL filtered virus-containing media, 4 µg/mL polybrene 
(Sigma), and 5 mL complete media.  At 24 hrs, the infection media was replaced with 
complete media.  At 48 hrs post- infection, cells were split into complete media containing 2 
µg/mL puromycin (Sigma) for selection of expressing populations. 
 
    Site-directed Mutagenesis.  Point mutations were engineered into pBScript wild type FAK 
template using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla CA).  
Sequence analysis was performed on each mutant to verify the intended point mutations and 
that no unintended mutations were present.  These analyses were performed in the UNC-CH 
Genome Analysis Facility on a model 3730 DNA Analyzer (Perkin Elmer, Applied 
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Biosystems Division) using the ABI PRISMTM Dye Terminator Cycle Sequencing Ready 
Reaction Kit with AmpliTaq DNA Polymerase, FS (Perkin Elmer, Applied Biosystems 
Division). 
 
    Protein analysis. Cells were washed twice with PBS and lysed in modified RIPA (50 mM 
Tris [pH 7.3], 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate) containing protease and 
phosphatase inhibitors as described previously (Gao et al., 2004).  Protein concentrations 
were determined with the bicinchoninic acid assay (Pierce, Rockford, Ill.). The FAK 
phosphorylation site-specific antibodies (Biosource International, Camarillo, CA) and 
paxillin, p130CAS, and PY20 phosphotyrosine antibodies (BD Biosciences, San Diego, CA) 
were purchased commercially.  The BC4 polyclonal antiserum has been described previously 
(Gabarra-Niecko et al., 2002).  Immunoprecipitations and Western blotting were performed 
as previously described (Gabarra-Niecko et al., 2002).  
 
    Immunofluorescence. Glass coverslips were coated with 50 µg/mL bovine plasma 
fibronectin (Sigma) in PBS for 1 hr at 37°C. Cells were plated onto the coated coverslips and 
maintained at 37°C for 16 hr.  GFP expressing cells were fixed in ice cold 95% ethanol.  
Cells were visualized using a Leitz Orthoplan fluorescence microscope, and images captured 
with a Hamamatsu digital camera and Metamorph imaging software (Universal Imaging 
Corporation, West Chester, PA).  Images were taken with identical exposure times.   
 
    Modified Boyden Chamber Assay.  Subconfluent fak -/- MEFs were serum-starved for 20 
hrs in DMEM supplemented with 0.5% FBS.  The undersides of 8 µm pore transwells were 
 42 
coated with 10 µg/mL bovine fibronectin for 2 hrs at 37oC.  The upper chamber was blocked 
with 0.05% lipid-free BSA in DMEM.  After fibronectin coating, the upper and lower 
chambers were blocked with 1% lipid-free BSA in DMEM for 1 hr at room temperature.  
Cells were trypsinized and washed twice with 0.5 mg/mL soy trypsin inhibitor.  1x105 cells 
were added to the upper chamber of the transwell and allowed to migrate though for 2.5 hrs 
at 37oC.  To terminate the assay, cells were removed from the upper chamber and chambers 
were washed in PBS, then fixed and stained using Hema3 kit.  Stain was eluted using 10% 
acetic acid and absorbance was measured at 668 nm. 
 
    In vitro kinase assay.  Transfected 293 cells were lysed in modified RIPA buffer at 72 hrs 
post-transfection.  FAK was immunoprecipitated from 0.2 mg lysate using polyclonal BC4 
antibody.  Immunoprecipitated protein was washed twice in lysis buffer, twice in PBS, then 
with kinase reaction buffer (50 mM HEPES [pH 7.4], 10 mM MnCl2).  Each reaction was 
resuspended in 20 µL kinase reaction buffer supplemented with 1 µM ATP and 10 µCi [?-
32P] ATP (PerkinElmer Life Sciences).  Reactions were incubated at room temperature for 3 
or 10 min before addition of 20 µL Laemmli sample buffer and boiling to elute the proteins.  
Samples were resolved by SDS-PAGE and phosphorylation was revealed by 
autoradiography.
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    3.3 RESULTS 
    Biochemical screening of FERM domain mutants.  FERM domain mutants of FAK have 
been reconstituted in fak -/- fibroblasts as described in materials and methods.  Expression of 
the mutants was confirmed by western blotting, as shown in Figure 10.  Cell lysates were 
used for western blotting using phosphospecific antibodies to FAK Y397 and Y576 as shown 
in Figure 11A.  None of the FERM domain mutants screened revealed any differences in 
phosphorylation of these sites on FAK.  Total FAK phosphorylation was also assessed for 
these mutants.  FAK was immunoprecipitated from lysates and immunoblotted for 
phosphotyrosine.  None of the FERM domain mutants screened displayed any defects in total 
FAK phosphorylation as detected by this method.   
    Although FAK phosphorylation appeared to be intact with these FERM domain mutants, 
downstream signaling could still be altered.  To assess downstream signaling of these FAK 
mutants, lysates from these cells were immunoprecipitated for paxillin and immunoblotted 
for phosphotyrosine, as shown in Figure 11B.  There were no measurable differences 
between paxillin phosphorylation in fak -/- MEFs reconstituted with wild type or mutant forms 
of FAK, indicating that these mutants do not biochemically affect FAK downstream 
signaling in these cells.    
 
    Biological screening of FERM domain mutants.  Although there were no striking 
biochemical differences detected with any of the mutant reconstituted fak -/- MEFs, there 
could still be mutants that affect FAK biological functions.  As described previously, the fak -
/- cells are useful tools to test for biological defects of FAK mutants because these cells are 
reported to be defective for several FAK-regulated cellular processes.  Based on published 
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reports, it seems that the interactions between the FERM domain of FAK with proteins such 
as PDGFR, EGFR, and Etk are important for regulating motility, but these findings are based 
on the analysis of large deletions rather than point mutations.   Furthermore, mutations that 
affect the association between the FERM and catalytic domains have been shown to alter 
cellular motility (Dunty et al., 2004;Cohen and Guan, 2005).  To identify FERM domain 
mutations of FAK that have defects in FAK biological activity, haptotactic motility was 
measured using modified Boyden chamber assays.   
    The FERM domain mutant-reconstituted fak -/- MEFs were used in modified Boyden 
chamber assays to assess haptotaxis as described in the materials and methods.  The results of 
these assays, shown in Figure 12 revealed statistically significant differences between wild 
type reconstituted cells and several of the mutant reconstituted cell lines.  Some of the 
mutations were unable to restore the motility defect of the fak -/- MEFs, such as E245A, 
K255A, and Q226A.  Other mutations increased motility to levels above that of wild type 
FAK, such as W266A/I268A and V270A/E271A.  The locations of these residues on the 
surface of the FERM domain structure are shown in Figure 13.  Mutation of these residues 
affects FAK biological function, indicating that these residues may be important for 
interactions that affect FAK signaling.  
 
    FAK FERM domain- catalytic domain interaction.  Collaborators have recently succeeded 
at co-crystallizing the FAK FERM and catalytic domains.  This has yielded novel structural 
information about the interface between these two domains of FAK.  Their work shows that 
the FERM domain F2 lobe binds to the C- lobe of the FAK catalytic domain.  This interaction 
is thought to be the major interface for the intramolecular inhibition of FAK.  To test whether 
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this is in fact the case, residues were selected to specifically disrupt this interface, in order to 
assess whether these mutations result in a constitutively activated form of the kinase as 
predicted.  Based on the co-crystallized structure, F596 and V196 were selected as the most 
important residues for the interaction in the catalytic and FERM domains, respectively.  The 
structure shows F596 projecting into a pocket on the surface of the FERM domain.  To 
disrupt the association, F596 was mutated to alanine.  In the FERM domain, V196 was 
mutated to phenylalanine to fill the pocket on the FERM domain and potentially occlude 
binding by the catalytic domain.  Both mutations have been tested to assess their biochemical 
and biological effects. 
 
    Biochemical characterization of interface mutants.  To assess the biochemical effects of 
mutations of key residues for the FERM-catalytic domain interaction, mutations were made 
and expressed as GFP-fusions in 293 cells.  Phosphorylation of FAK in these cells was 
measured using phosphospecific antibodies, as shown in Figure 14A.  Mutation of F596A 
resulted in dramatically increased phosphorylation of FAK at Y861 in cells growing in 
culture.  This mutation or mutation of V196F had little to no effect on phosphorylation of 
Y397, Y576, or Y577 in cells growing in culture.  In order to more clearly assess catalytic 
activity of these mutants, in vitro kinase assays were performed.  In cells growing in culture, 
neither of these mutations had any quantifiable difference in FAK autophosphorylation in 
vitro as shown in Figure 14B. 
    Given the nature of the interaction between the two FAK domains, it seems likely that the 
association should be strongest in conditions when the cell would want to most strongly 
negatively regulate FAK activity.  These conditions would include serum-starvation and 
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suspension.  Therefore to try to exacerbate differences between wild type and interface 
mutants of FAK, the above experiments were repeated following periods of serum-starvation 
and suspension (data not shown).  These experiments have revealed that the GFP-fused 
exogenous FAK constructs are not regulated by serum-starvation or by suspension in 293 
cells.  
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    3.4 DISCUSSION 
    FERM domain mutants.  Two mutations in the FAK FERM domain that yielded similar 
biological changes in FAK activity were W266A/I268A and V270A/E271A.  These 
mutations are adjacent both in sequence and on the surface of the FERM domain structure.  
Both mutations increased motility in fak -/- MEFs to levels above that of wild type FAK, 
suggesting that mutations in this region increase FAK function as detected biologically.  
Neither of these mutations altered FAK biochemically in these experiments, suggesting the 
effects on FAK function may not be very strong.  Mutagenesis of this region could affect 
FAK function in several ways.  This mutation could be non-specifically affecting the 
structure of FAK, however this is highly unlikely as these mutations are on the surface of the 
protein.  Alternatively, these mutations could disrupt binding of some protein to the FAK 
FERM domain.  This binding could regulate FAK activity in many ways, either by affecting 
the protein’s conformation state, phosphorylation state, or by affecting the binding of some 
other protein to FAK.  
    The sequence surrounding these two mutations, SWIISVE, may fit the consensus for a 
GSK-3 phosphorylation site, SXXXS(P).  This is a favorable hypothesis since GSK-3 has 
recently been identified to phosphorylate FAK in its FAT domain at S722, thus negatively 
regulating FAK activity (Bianchi et al., 2005).  Therefore, it seems possible that GSK-3 also 
phosphorylates FAK in its FERM domain at S265, negatively regulating FAK activity.  
Bianchi et al. found that GSK-3 phosphorylation of the FAK FAT domain played an 
important role in regulating FAK activity during cell spreading and migration (Bianchi et al., 
2005).  The current mutagenesis findings are consistent with a role for GSK phosphorylation 
in the negative regulation of FAK-regulated migration.   
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    There are currently no reports of S265 phosphorylation.  To test the proposed hypothesis 
of GSK-3 phosphorylation of FAK, the S265A and S265A/S269A mutations need to be 
characterized.  If these sites are phosphorylated to negatively regulate FAK function, then 
mutation of these serine residues to alanines should result in the same increases in motility 
when reconstituted into fak -/- MEFs as the W266A/I268A and V270A/E271A mutations. 
 
    FAK FERM domain- catalytic domain interaction.  Using the structure of the purified 
FERM domain of FAK bound to the purified catalytic domain of FAK, mutations were 
designed to disrupt the association.  These mutants were expressed as GFP-fusions in 293 
cells.  The only difference in FAK function for these mutants was an increase in 
phosphorylation of Y861 when the V596A mutation was expressed.  This tyrosine residue is 
thought to be important for FAK binding to p130CAS and downstream signaling (Lim et al., 
2004), indicating a possible activation of FAK function for this mutant in these cells.  
However, no other effects where observed when these mutants were expressed in these cells.  
This is in contrast to previous studies that suggest that mutations to disrupt the association 
between the FAK FERM and catalytic domains should have dramatic effects on FAK 
catalytic activity and downstream signaling.  This may indicate that the single point 
mutations were inadequate to disrupt the association between the FERM and catalytic 
domains.  To address this concern, the structure of the interface of the domains should be 
further analyzed to select additional mutations to more dramatically disrupt the association 
between the domains. 
    The lack of significant biochemical differences in these studies may also be explained by 
the use of different expression systems and cell types.  The present studies have indicated 
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that exogenously expressed FAK may exceed the ability of 293 cells to regulate FAK 
properly when challenged with serum-starvation or suspension.  Alternatively, the GFP tag at 
the N-terminus of FAK may interfere with FAK regulation in these cells by affecting the 
binding of regulatory proteins.  Further, the GFP tag could be disrupting binding between the 
FERM and catalytic domains of FAK.  This would explain why mutations to disrupt this 
association have no effect on FAK function in these studies.  To further study these mutants 
to understand whether they are able to disrupt binding between the FERM and catalytic 
domains, untagged constructs will need to be utilized in a cell type where exogenously 
expressed FAK protein can be regulated properly. 
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Table I.  Designed point mutations of the FAK FERM domain.  Based on 
evolutionary conservation between species, searches for known binding motifs,  
and using the structure of the FERM domain of FAK, novel point mutations were 
designed.  In addition to these novel FERM domain mutations, other mutations had 
been generated in the lab previously. 
 
Mutation Location 
P117A/E119A Acyl-CoA BP-like (F2) 
E158A/D161A Acyl-CoA BP-like 
D164A/E166A Acyl-CoA BP-like 
K190A/K191A Acyl-CoA BP-like 
R204A/R205A Acyl-CoA BP-like 
K216A/K218A/R222A Acyl-CoA BP-like 
T219A Acyl-CoA BP-like 
Q226A Acyl-CoA BP-like 
Q230A Acyl-CoA BP-like 
E245A Hinge between F2-F3 
R252A Hinge between F2-F3 
K255A Hinge between F2-F3 
K259A PH-like (F3) 
W266A/I268A PH-like 
V270A/E271A PH-like 
E277A/E278A PH-like 
I320A PH-like 
E338A/D342A PH-like 
 





  
 
 
 
CHAPTER FOUR 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
    Deviations from normal levels of angiogenesis play a role in several pathological 
conditions, such as stroke and coronary artery disease (Eliceiri and Cheresh, 2001).  
Angiogenesis requires the proper regulation of several cellular processes including cell 
growth, survival, and migration (Daniel and Abrahamson, 2000;Eliceiri and Cheresh, 
2001;Eliceiri, 2001;Orr and Murphy-Ullrich, 2004).  These processes are regulated by signals 
from integrins and growth factor receptors in vascular endothelial cells and also in 
fibroblasts.  An important protein known to play a role in the regulation of these angiogenic 
processes is the focal adhesion kinase (FAK).  FAK is activated by several angiogenic 
stimuli and FAK is important for regulating several cellular processes integral to 
angiogenesis, such as cell growth, survival, and migration.  FAK function is regulated in 
several ways and although much is known about phosphorylation events that play a role in 
FAK’s activation, the complete mechanism of activation still remains to be resolved.  The 
purpose of these studies was to gain further insight into the mechanisms of FAK activation.   
    FAK subcellular localization is critical for FAK function.  Understanding how this 
localization is mediated could be useful to help design drugs that could displace FAK and 
therefore disrupt FAK function in cells in which FAK-mediated cellular processes are 
misregulated.  This study has characterized the interaction between FAK and paxillin and the 
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importance of this association for FAK localization, activation, and downstream signaling.  
Paxillin binding is the major mechanism by which FAK localizes to focal adhesions, 
although this association is not absolutely required for FAK localization.  This indicates that 
there is a secondary mechanism by which FAK can target to focal adhesions in the absence 
of paxillin binding.  The present studies have identified a residue outside the paxillin-binding 
sites on FAK that appears to be responsible for this secondary mechanism of localization; 
however the protein responsible for binding to this residue remains to be identified.  
Complete characterization of the mechanisms by which FAK targets to focal adhesions is 
required before targeted disruption of FAK localization can be achieved. 
    Phosphorylation of FAK is know to regulate its function is several biological contexts.  
Although much is known about tyrosine phosphorylation of FAK and the resulting 
biochemical and biological effects, there have been relatively few studies that have identified 
or elucidated the functions of serine phosphorylation sites on FAK.  The present studies have 
identified several residues within the FAK FERM domain that seem to play a role in FAK 
regulation of haptotactic motility.  Two of these mutants indicate a possible role for GSK-3 
regulation of FAK via serine phosphorylation of the FAK FERM domain.  This hypothesis is 
supported by a recent report of GSK-3 serine phosphorylation of the FAK C-terminus 
(Bianchi et al., 2005).  Although GSK-3 phosphorylation of the FAK FERM domain remains 
to be demonstrated, GSK-3 regulation of FAK remains an interesting new area of study for 
FAK regulation.   
    Finally, the association between the FAK FERM and catalytic domains represents a novel 
mechanism of regulation of FAK.  Mutations to disrupt this association need to be 
characterized in order to understand the role of this regulatory association.  The present 
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studies have indicated that GFP-tagged constructs are not regulated properly when expressed 
in 293 cells.  In order to understand the role of this association on FAK regulation, untagged 
forms of the proteins need to be studied in a cell type where they are properly regulated.  
Understanding this intramolecular inhibition of FAK is important as this could represent a 
novel regulatory mechanism of FAK that could be manipulated in cells in order to 
manipulate FAK function when necessary. 
    These studies have gained interesting insight into the regulation of FAK in fibroblasts.  
Although these studies have interesting implications for therapeutics, the results from these 
studies should first be verified in vascular endothelial cells (ECs).  Although regulation of 
many processes is conserved between fibroblasts and ECs, there may be some differences in 
the responses of the mutant forms of FAK in these different cell types.  Therefore, 
biochemical and biological results obtained in fibroblasts should be confirmed in ECs in 
order to gain further insight into the regulation of FAK during angiogenesis.   
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